Text size
Francois Lo Presti / AFP via Getty Images
Pfizer and Moderna were first out of the gate with approved vaccines for Covid-19, but three other drugmakers are following in their footsteps and could help speed up the U.S. and other countries.
Novavax is launching a trial of 30,000 people in the US and Mexico for the vaccine, which could be approved as early as the spring of 2021.
Novavax
vaccine uses proteins to elicit an immune response after being injected, as well as a substance derived from Chilean evergreen trees to enhance the response.
Vaccines developed by AstraZeneca and Johnson & Johnson use viral vector technology, in which an altered virus elicits an immune response.
AstraZenecasay
the drug is expected to be approved in the UK this week, and the company said the vaccine should “remain effective” on the variant first discovered there.
More than two million Americans have been vaccinated to date
Pfizer
and Modern medicine, both of which use synthetic messenger RNA to activate the body to produce protective antibodies against the virus.
Having multiple vaccines increases the overall supply and offers options that can be more effective in different sections of the population. According to President of his Covid-19 Advisory Board, Joe Biden, Joe Biden prefers to also assist in the supply of juice by calling on the Defense Production Act.
This is an excerpt from The Barron’s Daily Newsletter. Sign in here.
Write to [email protected]